6th Annual Project & Portfolio Management in the Pharmaceutical Industry

Jacob Fleming Conferences28 - 29 September 2010, Milan, Italy.
After 5 successful annuals and the industry feedback, Jacob Fleming Conferences is bringing a well-balanced program full of real life case studies on major achievements in Project & Portfolio Management Approaches established across leading Pharma companies.

Testimonials
"Good balance of speakers, great learning experience and excellent chairman!"
Director Research Project Management, MedImmune, UK

"Very high-quality & influential speakers."
Portfolio Director, AstraZeneca, UK

"Very practical, inspiring and high-level agenda. Very good conclusions from the chairman."
Senior Portfolio Manager, GlaxoSmithKline, Belgium

Expert Advisors
Head of Discovery Research, Roche, Switzerland
Vice President Portfolio Management, Strategic Planning, Bayer Schering Pharma, Germany
Vice President Project Management R&D, Amgen, USA
Scientific Vice President, Novo Nordisk, Denmark
Head R&D Portfolio Management, UCB, UK
Executive Vice President & Chief Scientific Officer, Ipsen, France
Executive Vice President Research & Development, Nycomed, Germany

Key speakers
Vice President Special Operations, Worldwide Research Centers of Emphasis, Pfizer, UK
Global Head Portfolio Management & Reporting, Sanofi Aventis, France
Head Global Project Management, Abbott, Germany
Global Head of Portfolio Management & Interfaces Discovery Research and Oncology, MerckSerono, Switzerland
Head Portfolio Management, Bayer Schering Pharma, Germany
Vice President Research, Lundbeck, Denmark
Senior Project Leader Cancer Immunotherapeutics, GSK Biologicals, Belgium

Key topics

  • Explore the ways how leading Pharma companies develop their portfolios to add value to key stakeholders
  • Trends in portfolio offerings – more for physicians, payers or patients?
  • The impact of current payer-driven environment and cost-containment initiatives on managing R&D projects
  • Achieving a balanced, rich & varied portfolio in a competitive and limited resources environment
  • Innovative approaches to managing Discovery Projects
  • Project Management in Late stage Development Projects
  • Prioritization and decision analysis tools –decision making on innovation
  • Balancing the risks in Project & Portfolio Management - Risk Management in PPM
  • Enhancing the innovation & strong portfolios through R&D collaborations and M&A – the role of alliance management & business development

Who should attend
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Portfolio Management, Project Management, Pharmaceutical Development, R&D, Strategic Planning & Decision, Strategy & Portfolio Analysis, Portfolio Selection, Decision Analysis.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6thPPM?partner=worldpharmanewsPPM

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]